{
    "clinical_study": {
        "@rank": "163085", 
        "arm_group": [
            {
                "arm_group_label": "Oral disperion fasted", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions."
            }, 
            {
                "arm_group_label": "Capsule fasted", 
                "arm_group_type": "Experimental", 
                "description": "single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions"
            }, 
            {
                "arm_group_label": "Capsule fed", 
                "arm_group_type": "Experimental", 
                "description": "single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to test plasma exposure to PF-05089771 with same formulation will be used\n      for phase II trials (capsule)."
        }, 
        "brief_title": "Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive\n             (Healthy is defined as no clinically relevant abnormalities identified by a detailed\n             medical history, full physical examination, including blood pressure and pulse rate\n             measurement, 12-lead ECG and clinical laboratory tests).  Females must be of\n             non-childbearing potential.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  An informed consent document signed and dated by the subject or a legally acceptable\n             representative, indicating that the subject has been informed of all pertinent\n             aspects of the trial.\n\n          -  Subjects who are willing and able to comply with all scheduled visits, treatment\n             plan, laboratory tests, and other study procedures\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal (i.e recurrent\n             uric nephrolithiasis), endocrine, pulmonary, gastrointestinal, cardiovascular,\n             hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but\n             excluding untreated, asymptomatic, seasonal allergies at time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854996", 
            "org_study_id": "B3291020"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oral disperion fasted", 
                "description": "450mg", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug", 
                "other_name": "no specified"
            }, 
            {
                "arm_group_label": "Capsule fasted", 
                "description": "450mg", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug", 
                "other_name": "no specified"
            }, 
            {
                "arm_group_label": "Capsule fed", 
                "description": "450mg", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug", 
                "other_name": "no specified"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 24, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291020&StudyName=Relative%20Bioavailability%20with%20PF-05089771%20Capsule%20Versus%20Oral%20Dispersion"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Randomized, Single-Dose Study To Determine The Relative Bioavailability Of Capsule Vs Oral Dispersion And The Effect Of Food On The Pharmacokinetics Of Orally Administered PF-05089771 As Capsule In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants With Laboratory Test Values of Potential Clinical Importance", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}